Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 2/20 | 0.82 |
| ▸ | ECE2 | P0DPD6 | 2/20 | 0.78 |
| ▸ | ECE1 | P42892 | 2/20 | 0.78 |
| ▸ | MUS81 | Q96NY9 | 2/20 | 0.78 |
| ▸ | PGR | P06401 | 1/20 | 0.74 |
| ▸ | MEN1 | O00255 | 6/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.71 |
| ▸ | TP53 | P04637 | 1/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.71 |
| ▸ | HPGD | P15428 | 1/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.71 |
| ▸ | NPC1 | O15118 | 2/20 | 0.69 |
| ▸ | RAB9A | P51151 | 2/20 | 0.69 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.69 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.69 |
| ▸ | GAA | P10253 | 3/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1175103 | 1.00 | AR (0.82) | ARECE2ECE1MUS81PGR | |
| SCHEMBL29874298 | 1.00 | AR (0.82) | ARECE2ECE1MUS81PGR | |
| SCHEMBL1175104 | 1.00 | AR (0.82) | ARECE2ECE1MUS81PGR | |
| SCHEMBL4570233 | 0.91 | AR (0.76) | ARECE2ECE1MUS81PGR | |
| SCHEMBL14983767 | 0.90 | AR (1.00) | ARECE2ECE1MUS81PGR | |
| SCHEMBL4570236 | 0.88 | AR (0.80) | ARECE2ECE1MUS81PGR | |
| SCHEMBL14984011 | 0.88 | AR (0.76) | ARECE2ECE1MUS81PGR | |
| SCHEMBL14983781 | 0.88 | AR (0.76) | ARECE2ECE1MUS81PGR | |
| SCHEMBL14983950 | 0.88 | AR (0.76) | ARECE2ECE1MUS81PGR | |
| SCHEMBL14983945 | 0.88 | AR (0.76) | ARECE2ECE1MUS81PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200102264-A1 | MARMELIN ANALOGS AND METHODS OF USE IN CANCER TREATMENT | THE UNIVERSITY OF KANSAS (US) | 2020-04-02 | — | — | US | disclosed |
| US-20170144965-A1 | MARMELIN ANALOGS AND METHODS OF USE IN CANCER TREATMENT | THE UNIVERSITY OF KANSAS | 2017-05-25 | — | — | US | disclosed |
| US-20170144965-A1 | MARMELIN ANALOGS AND METHODS OF USE IN CANCER TREATMENT | THE UNIVERSITY OF KANSAS | 2017-05-25 | — | — | US | disclosed |
| US-9296716-B2 | Androgen receptor ligands | THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, & THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIV. TRINITY OF QUEEN ELIZABETH NEAR DUBLIN (IE) | 2016-03-29 | — | — | US | disclosed |
| US-9296716-B2 | Androgen receptor ligands | THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, & THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIV. TRINITY OF QUEEN ELIZABETH NEAR DUBLIN (IE) | 2016-03-29 | — | — | US | disclosed |
| WO-2015188130-A1 | MARMELIN ANALOGS AND METHODS OF USE IN CANCER TREATMENT | THE UNIVERSITY OF KANSAS (US) | 2015-12-10 | — | — | WO | disclosed |
| US-20140357682-A1 | ANDROGEN RECEPTOR LIGANDS | The Provost, Fellows, Foundation Scholars, & the Other Members of Board, of The College of the Holy (IE) | 2014-12-04 | — | — | US | disclosed |
| US-20140357682-A1 | ANDROGEN RECEPTOR LIGANDS | The Provost, Fellows, Foundation Scholars, & the Other Members of Board, of The College of the Holy (IE) | 2014-12-04 | — | — | US | disclosed |
| WO-2013076275-A1 | ANDROGEN RECEPTOR LIGANDS | THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, & THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY & UNDIV.TRINITY OF QUEEN ELIZABETH NEAR DUBLIN (IE) | 2013-05-30 | — | — | WO | disclosed |
| US-20110046101-A1 | BATE-LACTAMASE INHIBITORS | DMITRIENKO GARY I | 2011-02-24 | — | — | US | disclosed |
| US-20110046101-A1 | BATE-LACTAMASE INHIBITORS | DMITRIENKO GARY I | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200102264-A1 | MARMELIN ANALOGS AND METHODS OF USE IN CANCER TREATMENT | COIL, MUC1, MAN2B2 | AR 427/4885ECE2 4633/4885ECE1 4257/4885 |
| US-20170144965-A1 | MARMELIN ANALOGS AND METHODS OF USE IN CANCER TREATMENT | COIL, MUC1, MAN2B2 | AR 405/4885ECE2 4650/4885ECE1 4299/4885 |
| US-20110046101-A1 | BATE-LACTAMASE INHIBITORS | OXA1L, MGAM, PREP | AR 3584/4885ECE2 159/4885ECE1 61/4885 |
| US-20140357682-A1 | ANDROGEN RECEPTOR LIGANDS | AR, NR5A1, SHBG | AR 1/4885ECE2 3648/4885ECE1 3442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.